Naproxen Tablet, Delayed Release
Product Images NDC 70954-928

6 FDA label images from Ani Pharmaceuticals, Inc. · Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 6 technical images submitted to the FDA as part of the official labeling for Naproxen (NDC 70954-928). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Ani Pharmaceuticals, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Structure (Naproxen)

Structure (Naproxen)
Chemical structure of naproxen showing its molecular formula C14H14O3 and molecular weight 230.26. The structure includes a methoxy group (CH3O) attached to the naphthalene ring, with notation indicating the R group as a carboxylic acid (-COOH).*
FDA Label Image

Med Guide 1 (Med Guide 1)

Med Guide 1 (Med Guide 1)
A text panel listing risk factors or considerations related to the use of NSAIDs, including medical history items like stomach ulcers or bleeding, use of corticosteroids, anticoagulants, SSRIs, SNRIs, increasing doses and longer use of NSAIDs, lifestyle factors such as smoking and alcohol consumption, and conditions like older age, poor health, advanced liver disease, and bleeding problems.*
FDA Label Image

Med Guide 2 (Med Guide 2)

Med Guide 2 (Med Guide 2)
A text panel listing possible warning symptoms related to drug use, such as shortness of breath or trouble breathing, chest pain, weakness on one side of the body, slurred speech, and swelling of the face or throat. This content is part of patient safety information accompanying Naproxen delayed-release tablets.*
FDA Label Image

Med Guide 3 (Med Guide 3)

Med Guide 3 (Med Guide 3)
A text panel listing potential side effects or adverse symptoms associated with the medication Naproxen. The list includes symptoms such as nausea, diarrhea, itching, yellowing of skin or eyes, stomach pain, flu-like symptoms, vomiting blood, blood in bowel movements or black stools, unusual weight gain, skin rash or blisters with fever, and swelling of extremities.*
FDA Label Image

Label-1 (Label 1)

Label-1 (Label 1)
Label for Naproxen Delayed-Release Tablets, USP 375 mg by ANI Pharmaceuticals, Inc. The oral delayed-release tablets come in a container of 100 tablets. The label includes storage instructions, tamper-evident warnings, and a barcode, with the distributor located in Baudette, MN.*
FDA Label Image

Label-2 (Label 2)

Label-2 (Label 2)
Label for Naproxen Delayed-Release Tablets USP, 500 mg strength, oral dosage form. The label indicates 100 tablets per container and is labeled for prescription use only. Distributed by ANI Pharmaceuticals, Inc., with storage and dispensing instructions included. The label features a barcode and issuance date of 06/2024.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.